Gain Therapeutics reports positive financial results for Q1 2025, advancing lead drug candidate for Parkinson's

From GlobeNewswire: 2025-05-14 07:30:00

Gain Therapeutics, Inc. reported financial results for Q1 2025, highlighting the first administration of lead drug candidate GT-02287 for Parkinson’s disease. A Phase 1b study is ongoing, with enrollment expected to complete by July 2025. Results from a biomarker analysis are anticipated in mid-2025, informing Phase 2 planning for GT-02287.

In Q1 2025, Gain Therapeutics saw a decrease in R&D expenses and an increase in G&A expenses compared to Q1 2024. Net loss per share was $0.16 in Q1 2025, with cash and marketable securities totaling $9.1 million as of March 31, 2025.

GT-02287, an allosteric enzyme modulator, is the lead drug candidate being developed for Parkinson’s disease. Preclinical data shows promising results in restoring enzyme function and reducing neurodegenerative markers. Phase 1 study results demonstrated safety and target engagement, leading to the Phase 1b trial for PD treatment.

Gain Therapeutics is focused on developing next-generation allosteric therapies for various diseases. GT-02287 may have potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. The company utilizes the Magellan™ platform to accelerate drug discovery for neurodegenerative diseases, rare genetic disorders, and oncology.

Financially, Gain Therapeutics has a strong balance sheet with $5.8 million in stockholders’ equity as of March 31, 2025. The company continues to advance its clinical programs and aims to submit an IND to the FDA by the end of 2025. Investors and media inquiries can contact Gain Therapeutics for more information.



Read more at GlobeNewswire:: Gain Therapeutics Reports Financial Results for First